Contrary, Dimopoulos et al. could not identify any predictive value of CRBN, IKZF1, and IKZF3 for IMID response in 23 MM patients treated with a lenalidomide-containing regimen and argue against the use of these proteins as predictive biomarkers. This evidence concerns the gene CRBN and Miyoshi myopathy.